Trinity Capital announced the commitment of $25M in growth capital to Neuros Medical, a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life. Neuros Medical’s Altius System incorporates the company’s patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. The growth capital will enable Neuros Medical to augment the recent equity raised and further scale operations to assist with their commercial launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRIN:
- Trinity Capital Inc. Reports Third Quarter 2023 Financial Results
- These 12%-Plus Dividend Stocks Look Very Attractive Right Now, Analysts Say
- Trinity Capital Inc. Announces Adjustment to Conversion Rate of its 6.00% Convertible Notes due 2025
- Trinity Capital Inc. Declares Cash Dividend of $0.54 per Share for the Third Quarter of 2023, Including a Supplemental Cash Dividend of $0.05 per Share
- Trinity Capital increases Q3 dividend to 49c, declares 5c supplemental dividend
